Sex‐ and site‐specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort
2025

Circulating Lipocalin 2 and Colorectal Cancer Risk

Sample size: 2534 publication 10 minutes Evidence: moderate

Author Information

Author(s): Robin Reichmann, Katharina Nimptsch, Tobias Pischon, Marc J. Gunter, Mazda Jenab, Anne Kirstine Eriksen, Anne Tjønneland, Jürgen Janke, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Fabian Eichelmann, Giovanna Masala, Sabina Sieri, Fabrizio Pasanisi, Rosario Tumino, Maria Teresa Giraudo, Joseph Rothwell, Gianluca Severi, Paula Jakszyn, Maria-Jose Sánchez, Pilar Amiano, Sandra M. Colorado-Yohar, Marcela Guevara, Bethany van Guelpen, Elom K. Aglago, Alicia K. Heath, Karl Smith-Byrne, Elisabete Weiderpass, Krasimira Aleksandrova

Primary Institution: Leibniz Institute for Prevention Research and Epidemiology

Hypothesis

Is there an association between pre-diagnostic circulating lipocalin 2 concentrations and incident colorectal cancer?

Conclusion

Higher pre-diagnostic concentrations of lipocalin 2 are associated with an increased risk of colon cancer, especially in women and those with abdominal adiposity.

Supporting Evidence

  • LCN2 concentrations were positively associated with higher waist circumference and physical inactivity.
  • The association between LCN2 and colon cancer was stronger in women than in men.
  • Participants with high waist circumference showed a positive association with colon cancer risk.

Takeaway

This study found that a protein called lipocalin 2 in the blood can help predict the risk of getting colon cancer, particularly in women and people with extra belly fat.

Methodology

A nested case-control study within the EPIC cohort, measuring lipocalin 2 in 1267 colorectal cancer cases and 1267 matched controls.

Potential Biases

Potential reverse causality as some cases may have had undiagnosed cancer at recruitment.

Limitations

Data on several covariates were incomplete, and the study relied on single measurements of lipocalin 2.

Participant Demographics

Participants aged 25-70 years from 10 European countries, with a balanced gender distribution.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI: 1.16 [0.98–1.37] for CRC overall

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/ijc.35205

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication